Dec 10 (Reuters) - Ligand Pharmaceuticals LGND.O:
LIGAND HOSTS 2024 INVESTOR AND ANALYST DAY AND INTRODUCES 2025 GUIDANCE
LIGAND PHARMACEUTICALS INC -2025 FULL YEAR REVENUE GUIDANCE OF $180 MILLION TO $200 MILLION
LIGAND PHARMACEUTICALS INC - OUTLOOK 2025 FULL YEAR CORE ADJUSTED EARNINGS PER DILUTED SHARE OF $6.00 TO $6.25
LIGAND PHARMACEUTICALS INC -WILL REITERATE ITS 2024 GUIDANCE OUTLINED IN NOVEMBER
Source text: ID:nBwcgVMZNa
Further company coverage: LGND.O
((Reuters.Briefs@thomsonreuters.com;))